Departments
Association Report
Pharmacists a valuable resource for patients with Alzheimer disease and their caregivers

https://doi.org/10.1016/j.japh.2019.09.020Get rights and content

Section snippets

Addressing the complex needs of a patient with Alzheimer disease

Alzheimer disease (AD) is one of the most common types of dementia in older adults.1 In 2017, approximately 46.7 million Americans had preclinical AD, and about 6.08 million Americans had either clinical AD or mild cognitive impairment due to AD.2 By 2060, the number of adults with clinical AD or mild cognitive impairment due to AD is expected to grow to 15 million.2 Not every patient with preclinical AD will progress to have clinical disease; however, both primary and secondary prevention of

Laressa Bethishou, PharmD, BCPS, APh, Assistant Professor of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA

References (22)

  • R. Brookmeyer et al.

    Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States

    Alzheimers Dement

    (2018)
  • K.J. Anstey et al.

    Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies

    Am J Geriatr Psychiatry

    (2009)
  • A. Rocchi et al.

    The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects

    Curr Alzheimer Res

    (2009)
  • S.J. Roriz-Filho et al.

    (Pre)diabetes, brain aging, and cognition

    Biochim Biophys Acta

    (2009)
  • E.K. Naderali et al.

    Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age

    Am J Alzheimers Dis Other Demen

    (2009)
  • S.M. de la Monte

    Insulin resistance and Alzheimer’s disease

    BMB Rep

    (2009)
  • D.E. Bredesen

    Reversal of cognitive decline: a novel therapeutic program

    Aging (Albany, NY)

    (2014)
  • B.T. Winslow et al.

    Treatment of Alzheimer disease

    Am Fam Phys

    (2011)
  • V. Solfrizzi et al.

    Diet and Alzheimer’s disease risk factors or prevention: the current evidence

    Expert Rev Neurother

    (2011)
  • M. Farlow et al.

    Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease

    BMC Neurol

    (2011)
  • S.S. Gill et al.

    Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study

    Arch Intern Med

    (2009)
  • Cited by (0)

    Laressa Bethishou, PharmD, BCPS, APh, Assistant Professor of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA

    Jelena Lewis, PharmD, BCACP, APh, Assistant Professor of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA

    View full text